ACE Inhibitors Improve Skeletal Muscle by Preserving Neuromuscular Junctions in Patients with Alzheimer’s Disease
Journal of Alzheimer's Disease · 18.07.2023 · 94 (2) · 641-650
DOI: 10.3233/jad-230201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 18.07.2023. Verfasst von Rizwan Qaisar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Alzheimer Disease, Hypertension. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Hypertension and skeletal muscle decline are common findings in patients with Alzheimer’s disease (AD). Angiotensin-converting enzyme (ACE) inhibitors preserve skeletal muscle and physical capacity; however, the driving mechanisms are poorly understood.
Objective
We investigated the effects of ACE inhibitors on the neuromuscular junction (NMJ) with relevance to skeletal muscle and physical capacity in AD patients and age-matched controls.
Methods
We evaluated controls (n = 59) and three groups of AD patients, including normotensive (n = 51) and patients with hypertension taking ACE inhibitors (n = 53) or other anti-hypertensive medications (n = 49) at baseline and one year later. We measure plasma c-terminal agrin fragment-22 (CAF22) as a marker of NMJ degradation, handgrip strength (HGS), and Short Physical Performance Battery (SPPB) as markers of physical capacity.
Results
At baseline AD patients demonstrated lower HGS and SPPB scores and higher CAF22 levels than controls, irrespective of the hypertension status (all p < 0.05). The use of ACE inhibitors was associated with higher HGS and relative maintenance of SPPB scores, gait speed, and plasma CAF22 levels. Conversely, other anti-hypertensive medications were associated with an unaltered HGS, reduced SPPB scores and elevated plasma CAF22 levels (both p < 0.05). We also found dynamic associations of CAF22 with HGS, gait speed, and SPPB in AD patients taking ACE inhibitors (all p < 0.05). These changes were associated with reduced oxidative stress in AD patients taking ACE inhibitors (p < 0.05).
Conclusion
Altogether, ACE inhibitors are associated with higher HGS, preserved physical capacity, and the prevention of NMJ degradation in hypertensive AD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
- Cardiovascular Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
- Department of Neurology and Stroke Medicine, Rehman Medical Institute, Peshawar, Pakistan.
- Exercise Physiology Department, College of Sport Sciences and Physical Activity, King Saud University, Riyadh, Saudi Arabia.
- Department of Biomedical Sciences, College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Zitieren
APA
Qaisar, R., Karim, A., Iqbal, M. S., Alkahtani, S. A., Ahmad, F., & Kamli, H. (2023). ACE Inhibitors Improve Skeletal Muscle by Preserving Neuromuscular Junctions in Patients with Alzheimer’s Disease. Journal of Alzheimer's Disease, 94(2), 641-650. https://doi.org/10.3233/jad-230201
Vancouver
Qaisar R, Karim A, Iqbal MS, Alkahtani SA, Ahmad F, Kamli H. ACE Inhibitors Improve Skeletal Muscle by Preserving Neuromuscular Junctions in Patients with Alzheimer’s Disease. Journal of Alzheimer's Disease. 2023;94(2):641-650. doi:10.3233/jad-230201
BibTeX
@article{Qaisar2023,
author = {Qaisar, Rizwan and Karim, Asima and Iqbal, M Shahid and Alkahtani, Shaea A and Ahmad, Firdos and Kamli, Hossam},
title = {ACE Inhibitors Improve Skeletal Muscle by Preserving Neuromuscular Junctions in Patients with Alzheimer’s Disease},
journal = {Journal of Alzheimer's Disease},
year = {2023},
volume = {94},
number = {2},
pages = {641--650},
doi = {10.3233/jad-230201}
}
EUVIMED